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Cancer-related indoleamine (2,3)-dioxygenase up-regulation by interferon-g might inﬂuence quality of life by depleting serum
tryptophan. We correlated serum tryptophan levels with immune activation and quality of life in patients with colorectal liver
metastases. Venous blood was sampled from patients with primary colorectal cancer and from patients with metachronous
colorectal liver metastases who completed quality of life and psychological questionnaires. Serum tryptophan, kynurenine,
neopterin, interleukin 2 soluble receptor a (IL-2 sRa), soluble tumour necrosis factor receptor I (sTNF RI), interleukin 6, and
C-reactive protein were measured. Liver metastasis volume was estimated by computerised tomography, and survival from
blood sampling was noted. Sixty-six patients with colorectal cancer were studied (39 males; median age 66 years) of whom 25
had colorectal liver metastases only (17 males; median age 62 years; median liver metastasis volume 208 ml; median survival
234 days). Reduced serum tryptophan was signiﬁcantly associated with Rotterdam Symptom Checklist physical symptom
(r=70.51, P=0.01) and Sickness Impact Proﬁle (r=70.42, P=0.04) scores, and correlated with increased serum neopterin
(r=70.36, P=0.003), IL-2 sRa (r=70.51, P=0.01) and sTNF RI (r=70.45, P=0.02) levels. Stepwise regression analyses
suggested that serum tryptophan was an independent predictor of Rotterdam Symptom Checklist physical symptom
(regression coefﬁcient 720.78, P=0.01) and Sickness Impact Proﬁle (regression coefﬁcient 7109.09, P=0.04) scores. The
results supported a role for interferon-g-mediated serum tryptophan decrease in cancer-induced quality of life deterioration.
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One explanation for the deterioration in the quality of life (QoL)
of colorectal cancer patients (Earlam et al, 1996) is an immune
response to tumour-related products. In support of this, QoL
impairment in colorectal liver metastasis (CLM) patients has been
shown to correlate more closely with extent of immune activation
than with liver metastasis volume or the serum level of the tumour
marker carcinoembryonic antigen (CEA) (Allen-Mersh et al, 1998).
In addition, animal studies suggest that immune activated cyto-
kines induce sickness behaviour (Dantzer et al, 1998) that is
similar to QoL impairment in humans (Bauhofer et al, 2001).
However, a mechanism by which tumour-related immune activa-
tion could result in QoL deterioration has not been identiﬁed.
The Th1 immune response stimulates the release of interferon-g
which induces the enzyme indoleamine (2,3)-dioxygenase (IDO)
(Murr et al, 2000). This increases degradation of tryptophan to
kynurenine (Werner et al, 1989), thereby reducing serum trypto-
phan (Gasse et al, 1998) and releasing kynurenine which is then
rapidly degraded (Denz et al, 1993). The neurotransmitter seroto-
nin is synthesised from tryptophan, and decreased levels of
tryptophan, serotonin and 5-hydroxyindoleacetic acid (the princi-
pal serotonin catabolite) can be associated with depression
(Owens and Nemeroff, 1994; Smith et al, 1999). Treatment with
selective serotonin reuptake inhibitors may alleviate this depression
(DeVane, 1998), but serum tryptophan depletion can also result in
transient, incomplete relapse (Smith et al, 1997). Although the
contribution of reduced serum tryptophan to depression remains
controversial, the ﬁnding of decreased tryptophan in both haema-
tological (Denz et al, 1993) and non-haematological (Iwagaki et al,
1997) malignancies, suggests a mechanism by which cancer-related
immune stimulation might inﬂuence QoL (Murr et al, 2000).
In this study, we measured serum tryptophan and kynurenine
levels in patients with colorectal cancer, and correlated these levels
with immune activation and QoL in CLM patients.
PATIENTS AND METHODS
Patients studied and blood sampling
All cancer patients had histologically-proven adenocarcinoma of
the colon or rectum. Consecutive patients with primary colorectal
cancer were studied prior to tumour resection, and showed no
evidence of metastases on pre-treatment abdominal CT scan or
chest radiograph. CLM patients had undergone primary colorectal
cancer resection more than 3 months and less than 24 months
previously, and had typical features of liver metastases on hepatic
computerised tomographic (CT) scan, together with a rising serum
CEA level. These patients had failed to respond to 1st line
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www.bjcancer.comchemotherapy (5-ﬂuorouracil and folinic acid) and were being
considered for percutaneous liver metastasis cryotherapy (Huang
et al, 2002). Patients were allocated to a ‘weight loss’ group if they
had lost more than 1 kg in body-weight during the previous month
and otherwise to a ‘stable weight’ group (Fordy et al, 1999).
Patients with extra-hepatic metastases on abdominal or pelvic CT
scan, or on thoracic radiograph, and patients receiving anti-depres-
sant, cytotoxic or corticosteroid treatments were excluded.
Subjects with no history of cancer, undergoing herniorraphy or
haemorrhoidectomy, were included as ‘no-cancer’ controls.
Ten millilitre of peripheral venous blood was sampled at 0800 h
in the morning after overnight fasting, and the serum stored at
7208C until assayed.
Serum tryptophan and kynurenine measurements
Serum free tryptophan and kynurenine concentrations were
measured by reverse-phase high-pressure liquid chromatography
after precipitation of protein with trichloroacetic acid. Tryptophan
was measured by ﬂuorescence detection at 285 nm excitation wave-
length and 365 nm emission wavelength; kynurenine was measured
by UV-absorption of 360 nm wavelength (Fuchs et al, 1990). The
mean values from previous measurements – in 49 healthy indivi-
duals – within our laboratory (Widner et al, 1997) were:
tryptophan 73.0 mmol l
71 (standard deviation [s.d.]+14.9),
kynurenine 1.9 mmol l
71 (s.d.+0.6) and kynurenine/tryptophan
ratio 26.9610
73 (s.d.+8.1610
73).
Serum immune product measurements
Serum neopterin was measured using radioimmunoassay (double
antibody technique). Normal serum value reported by the supplier
(Brahms Diagnostica GmbH, Berlin, Germany) was: mean
5.4 nmol l
71 (s.d.+2.3) with an upper normal limit of
10 nmol l
71. Serum interleukin 2 soluble receptor a (IL-2 sRa),
soluble tumour necrosis factor receptor I (sTNF RI) and interleu-
kin 6 (IL-6) were measured using enzyme-linked immunosorbent
assays. Normal serum values reported by the supplier (R&D
Systems Europe Ltd., Abingdon, UK) were: IL-2 sRa, median
1346 ng l
71 (range 676–2132), sTNF RI, 1198 ng l
71 (749–
1966), IL-6, 1.6 ng l
71 (0.4–10.1). The upper value in each range
was taken as the upper limit of normal. The IL-2 sRa assay coefﬁ-
cients of variation were56.1% (intra-assay) and57.2% (inter-
assay), and those for other assays were within a similar range.
Serum C-reactive protein (CRP) was measured by an automated
immunoturbidimetric assay on an Olympus AU600 analyser
(Olympus Diagnostic Systems, Eastleigh, UK), and a serum CRP
concentration of 10 mg l
71 was taken as the upper limit of
normal.
Liver metastasis volume, survival and QoL measurements
in CLM patients
Within 3 weeks of blood sampling, liver metastasis volume was
measured by CT scan as previously described (Dworkin et al,
1995). Survival was measured in days from the date of blood
sampling.
On the day of blood sampling, patients completed the following
QoL and psychological questionnaires: Rotterdam Symptom
Checklist (RSC) (de Haes et al, 1990), Hospital Anxiety and
Depression scale (HAD) (Zigmond and Snaith, 1983), and the
Sickness Impact Proﬁle (SIP) (Bergner et al, 1981).
Statistical analysis
Differences between groups in serum tryptophan, kynurenine and
kynurenine/tryptophan ratio were assessed by Mann–Whitney U-
(MWU) test. Spearman rank correlation (Langley, 1979) and step-
wise multiple regression analysis (Dixon, 1992a) were used for
statistical analyses as indicated. Tumour volume and serum levels
were not normally distributed and the interquartile ranges (iqr,
25th to 75th percentile) around the median were therefore used;
natural logarithms were also used to ensure normality before the
model was ﬁtted in regression. Similarly, the natural logarithm of
survival was used as an independent variable in stepwise multiple
regression analysis when the QoL score was the dependent variable.
Survival was included as an independent variable in case other
variables were dependent on it. The regression analyses excluded
patients who were still alive (four out of 25 patients) at the
completion of follow-up. Variables on these four patients were
within the interquartile ranges and therefore unlikely to distort
ﬁndings by their exclusion. Multivariate analyses assessing whether
the levels of serum immune products, tryptophan and kynurenine
contributed to variability in QoL scores used both natural loga-
rithms of continuous and binary transformed (above/below
upper and lower limits of normal/percentile as appropriate) vari-
ables. P values below 0.05 were considered statistically signiﬁcant.
The study was approved by the Chelsea and Westminster Hospi-
tal Research Ethics Committee and patients gave informed consent
before participation in the study.
RESULTS
Patients
One hundred and three patients [66 colorectal cancer patients (39
males; median age 66 years, iqr 61–73) and 37 ‘no-cancer’ controls
(13 males; median age 69 years, iqr 64–76)] were studied.
Serum immune product levels were measured in 25 of the color-
ectal cancer patients who had liver metastases (17 males; median
age 62 years, iqr 56–64) and who had also completed QoL ques-
tionnaires (Table 1). Median survival from blood sampling for liver
metastasis patients was 234 days (iqr 165–387), with four of the
liver metastasis patients surviving at the end of follow-up (25,
28, 32, and 35 months from blood sampling).
Serum tryptophan, kynurenine, and neopterin levels
The serum kynureinine/tryptophan ratio and neopterin were signif-
icantly increased and serum tryptophan signiﬁcantly reduced in
colorectal cancer compared with control patients (Table 2). There
was a signiﬁcant correlation between the kynurenine/tryptophan
ratio and serum neopterin in both colorectal cancer patients
(Spearman rank correlation, r=0.63, P50.0001, 95% conﬁdence
interval [95% CI]=0.45 to 0.75, n=66) and in ‘no-cancer’ controls
(r=0.54, P=0.0005, 95% CI=0.26 to 0.74, n=37).
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Table 1 Liver metastasis volume, serum immune product levels and
quality of life scores in 25 colorectal liver metastasis patients (17 males;
median age 62 years, iqr 56–64)
Variable Median iqr
Liver metastasis volume (ml) 208 121–707
Serum IL-2 sRa (ng l
71) 2207 1475–3205
Serum sTNF RI (ng l
71) 3020 1801–3807
Serum IL-6 (ng l
71) 9 6–69
Serum CRP (mg l
71) 19.3 3.5–53.8
RSC physical 8 5–17
RSC psychological 6 3–9
HAD depression 3 1–5
HAD anxiety 5 2–8
Sickness Impact Proﬁle 46.1 17.2–110.7
iqr=interquartile range; IL-2 sRa=interleukin 2 soluble receptor a; TNF RI=tumour
necrosis factor receptor I; IL-6=interleukin 6; CRP=C-reactive protein;
RSC=Rotterdam Symptom Checklist; HAD=Hospital Anxiety and Depression Scale.
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tryptophan level in colorectal cancer patients with liver metastases
(median 48.5 mmol l
71, iqr 43.3–56.4) compared with those with
primary tumour but no metastases (median 57.0 mmol l
71, iqr
48.8–64.4). Serum tryoptophan level was signiﬁcantly lower
(MWU, p=0.01) in liver metastasis patients who had lost 41k g
in body weight during the preceding month (n=3, median
33.1 mmol l
71, iqr 30.1–34.5) compared with those who had not
(n=16, median 45.3 mmol l
71, iqr 43.2–53.1). There were no
signiﬁcant correlations between serum tryptophan, and liver metas-
tasis volume or extent of survival in liver metastasis patients.
Relation between serum tryptophan and QoL in liver
metastasis patients
There were signiﬁcant correlations (Spearman rank correlation)
between reduced serum tryptophan level, and increased RSC physi-
cal and SIP scores (Figure 1), but not HAD depression, HAD
anxiety or RSC psychological scores. Stepwise multiple regression
analysis, including survival, tumour volume and serum immune
product levels as independent variables, selected serum tryptophan
as the most signiﬁcant independent predictor of RSC physical
symptom score, and a signiﬁcant independent predictor of SIP
score (Table 3). A similar result was obtained using binary variables
(normal/elevated serum levels). If included in the regression analy-
sis, serum neopterin was selected before serum tryptophan level.
Serum tryptophan was not selected as an independent predictor
of other QoL variables.
Serum tryptophan and immune products in liver
metastasis patients
Reduced serum tryptophan signiﬁcantly correlated with serum IL-2
sRa (Spearman rank correlation, r=70.51, P=0.01, 95% CI=70.76
to 70.15, n=25) and sTNF RI (r=70.45, P=0.02, 95% CI=70.72
to 70.07, n=25), but not with IL-6 or CRP.
DISCUSSION
Although fatigue or depression affects most patients with cancer
(Stone et al, 2000), the underlying mechanisms are still poorly
understood (Curt, 2001). The associations identiﬁed in the present
study do not establish cause and effect, but they are consistent with
QoL deterioration being inﬂuenced by an interferon-g-mediated
reduction in serum tryptophan. Multiple analyses were performed
on a limited number of patients in the present study. However,
the statistical signiﬁcance of tryptophan depletion in colorectal
cancer (Table 2), and of the association between serum tryptophan
level and QoL in regression analysis, remained after Bonferroni
correction (Dixon, 1992b).
Activated T lymphocytes release interferon-g which stimulates
macrophage production of neopterin. As a result there is a close
correlation between interferon-g activity and serum neopterin level
(Murr et al, 1999). The correlations between serum neopterin and
the serum kynurenine/tryptophan ratio in both colorectal cancer
patients and in ‘no cancer’ controls, and the rise in the kynure-
nine/tryptophan ratio in colorectal cancer patients suggested an
interferon-g-induced increase in IDO activity (Murr et al, 2000)
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Table 2 The ﬁndings of an increase in serum kynurenine:tryptophan ratio and reduction in serum tryptophan and neopterin, in colorectal cancer com-
pared with control patients, were consistent with an Th1 interferon-g-induced increase in hepatic indoleamine (2,3)-dioxygenase activity
Patients with colorectal cancer
(n=66 (39 men),
median age=66 years, iqr 61–73)
‘No-cancer’ control subjects
(n=37 (13 men),
median age=69 years, iqr 64–74)
Variable median iqr median iqr P (Mann–Whitney U-test)
Serum tryptophan (mmol l
71) 53.5 43.7–58.8 63.7 58.1–69.4 50.0001
Serum kynurenine (mmol l
71) 2.1 1.8–2.7 2.0 1.7–2.4 0.49
Serum kynurenine/tryptophan ratio (610
73) 42.9 35.1–54.9 31.8 27.7–37.2 50.0001
Serum neopterin (nmol l
71) 8.7 6.1–15.2 6.5 4.9–7.9 0.001
iqr=interquartile range.
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Figure 1 Reduced serum tryptophan correlated signiﬁcantly (Spearman
rank correlation) with quality of life deterioration in 25 patients with
colorectal liver metastases only (upper, Rotterdam Symptom Checklist
physical score, r=70.51, P=0.01, 95% CI=70.75 to 70.14; lower, Sick-
ness Impact Proﬁle score, r=70.42, P=0.04, 95% CI=70.70 to 70.03)
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would not be expected because of rapid kynurenine metabolism
(Denz et al, 1993). The negative correlation of the serum trypto-
phan level with IL-2 sRa and sTNF RI was compatible with a
Th1 immune response (Mills et al, 1993; Diez-Ruiz et al, 1995)
releasing interferon-g to induce tryptophan degradation (Murr et
al, 2000).
Cachexia studies in pancreatic cancer have suggested (Preston et
al, 1998) that a tumour-associated acute phase protein response
induces ﬁbrinogen synthesis at the expense of skeletal muscle
reserves. The greater aromatic amino acid (mostly tryptophan)
content in ﬁbrinogen compared with skeletal muscle proteins,
may then result in tryptophan depletion. Unlike pancreatic cancer,
signiﬁcant weight loss in colorectal cancer is usually associated with
a large tumour burden (Fordy et al, 1999). Our results suggested a
substantial serum tryptophan reduction (48% compared with ‘no-
cancer’ controls), in the small number of colorectal liver metastasis
patients with a history of more than 1 kg weight loss over the
previous month. However, the absence of a signiﬁcant association
between serum CRP (an indicator of the extent of acute phase
protein response) and serum tryptophan level, and the ﬁnding of
reduced serum tryptophan in the majority of colorectal cancer
patients without weight loss, did not suggest that our results could
entirely be explained by muscle wasting associated with tryptophan
depletion. It is possible that both an interferon-g-induced increase
in IDO activity and acute phase protein synthesis, were part of a
host response to colorectal carcinoma that depleted the serum of
tryptophan.
We cannot explain the difference between our results and some
earlier reported ﬁndings of elevated levels of plasma free trypto-
phan in animals (Krause et al, 1979) and patients (Cangiano et
al, 1990) with cancer – particularly those with anorexia (Chance
et al, 1983; Fanelli et al, 1986). In the present study, laboratory
analysis was carried out on mixed batches of control and cancer
patient samples without knowledge of the patient source. The
results showed a statistically signiﬁcant 16% lowering of serum
tryptophan among colorectal cancer patients (24% in liver metas-
tasis patients) compared with ‘no cancer’ controls, and this was
compatible with other more recent results reported for patients
with a variety of cancer types (Denz et al, 1993; Giusti et al,
1996; Iwagaki et al, 1997).
Studies in non-cancer patients with depression suggest that
rapid tryptophan depletion to roughly 20% of normal plasma levels
(Delgado et al, 1990; Smith et al, 1999) can induce a relapse of
depression (Moore et al, 2000). Acute tryptophan depletion of a
similar magnitude in healthy volunteers has been associated with
impairment of long-term memory (Riedel et al, 1999). The cogni-
tive effect of a chronic 10–20% serum tryptophan lowering
(probably double this in patients with cachexia), is unknown.
The selection in regression analysis of serum neopterin as the
strongest independent predictor of RSC physical and SIP scores
was consistent with an association between interferon-g up-regula-
tion and adverse QoL. The elimination of serum tryptophan level
from QoL regression analyses where serum neopterin was included,
suggested that serum neopterin and tryptophan levels provided
similar information about QoL prediction, and this would be
expected from the metabolic relationship between interferon-g
up-regulation and IDO-mediated tryptophan degradation. When
serum neopterin was excluded from the regression analysis, then
reduced serum tryptophan was selected as an independent predic-
tor of deterioration in RSC physical and SIP scores (Table 3).
These ﬁndings were consistent with an interferon-g-mediated
serum tryptophan decrease leading to QoL impairment in cancer
patients.
In addition to serum neopterin and tryptophan, serum IL-2 sRa
and TNF RI levels were also selected as independent predictors of
QoL deterioration. Thus the results suggested that a variety of
immune-related factors inﬂuenced QoL in CLM patients (Allen-
Mersh et al, 1998). Immune cytokines have overlapping functions
and act synergistically with each other in a concerted manner, so
that small alterations in particular combinations of cytokines can
have larger effects. Cytokines are capable of a wide array of direct
interactions – for example with central nervous system (Maes et
al, 1995; Zalcman et al, 1994), liver, and muscle receptors (Beutler
et al, 1985) – as well as mediating wasting (Fordy et al, 1999) in
colorectal cancer.
Although tryptophan supplementation has been used to treat
depression (DeVane, 1998), such an approach would be unlikely
to be effective where there is cancer-related IDO induction, because
this would increase IDO-associated neurotoxic metabolites – such
as quinolinic acid (Saito et al, 1992). Serum tryptophan depletion
is thought to inﬂuence mood in healthy subjects by the impairment
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Table 3 Stepwise regression analysis with continuous variables usiung Rotterdam
Symptom Checklist physical symptom score (above) and Sickness Impact proﬁle (be-
low) as the dependent variable. Serum tryptophan level was selected as a predictor
of both dependent quality of life variables
Step 0 Step 1
Independent variable
Regression
coefﬁcient (s.e.) P
Regression
coefﬁcient (s.e.) P
Tryptophan 720.78 (7.58) 0.01 720.78 (7.58) included
CRP 0 0.051 0 0.11
Kynurenine 0 0.25 0 0.14
IL-6 0 0.18 0 0.23
Liver metastasis volume 0 0.65 0 0.45
Survival 0 0.86 0 0.64
sTNF RI 0 0.09 0 0.66
IL-2 sRa 0 0.36 0 0.99
IL-6 5.83 (2.55) 0.03 5.32 (2.42) included
Tryptophan 0 0.06 7109.09 (57.17) 0.04
Kynurenine 0 0.69 0 0.09
sTNF RI 0 0.14 0 0.48
CRP 0 0.06 0 0.57
IL-2 sRa 0 0.42 0 0.95
Liver metastasis volume 0 0.81 0 0.98
Survival 0 0.57 0 0.99
See Table 1 for key to abbreviations; s.e.=standard error.
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Selective serotonin reuptake inhibitors (SSRI) have been reported
to improve depression in advanced cancer (Holland et al, 1998),
and in melanoma treated with interferon a (Musselman et al,
2001) since the latter also upregulates IDO (Taylor and Feng,
1991). However, these SSRI antidepressant effects might not
depend on IDO-mediated serum tryptophan reduction, and studies
of the effect of IDO inhibitors (Yuan et al, 1998) on cancer-related
QoL deterioration would be needed to conﬁrm the mechanism
suggested by the present ﬁndings.
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